
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Telomir Pharmaceuticals, Inc. Common Stock (TELO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TELO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -45.26% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.54M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 |
52 Weeks Range 1.52 - 8.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -391.62% | Return on Equity (TTM) -872.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46827162 | Price to Sales(TTM) - |
Enterprise Value 46827162 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 29762700 | Shares Floating 17618311 |
Shares Outstanding 29762700 | Shares Floating 17618311 | ||
Percent Insiders 34.17 | Percent Institutions 12.53 |
Upturn AI SWOT
Telomir Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing therapies to address age-related diseases and conditions, including cardiovascular, metabolic and neurodegenerative conditions. The company's lead product is Telomir-1, a small molecule compound.
Core Business Areas
- Drug Development: Focused on developing and commercializing Telomir-1, a small molecule compound targeting age-related diseases.
Leadership and Structure
The company has a management team leading its development efforts. Details of the specific structure can be found on its investor relations website or SEC filings.
Top Products and Market Share
Key Offerings
- Telomir-1: Telomir-1 is their lead product candidate, a small molecule compound aimed at treating age-related diseases. It is in the pre-clinical stage. Competitors are other companies developing therapies for age-related diseases.
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive and heavily regulated. Demand for treatments for age-related diseases is increasing due to the aging global population.
Positioning
Telomir Pharmaceuticals is positioned as a company developing innovative therapies in the age-related disease space. Being pre-clinical, it faces competition from larger, more established pharmaceutical companies with existing products or late-stage clinical trials.
Total Addressable Market (TAM)
The TAM for age-related disease therapeutics is substantial, potentially in the hundreds of billions of dollars. Telomir Pharmaceuticals' position depends on the successful development and commercialization of Telomir-1.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Focus on unmet medical needs
- Experienced management team (needs verification from source documents)
Weaknesses
- Pre-clinical stage of development
- Limited financial resources
- Dependence on single drug candidate
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Inability to raise sufficient capital
Competitors and Market Share
Key Competitors
- CRISPR Therapeutics (CRSP)
- BioAge Labs
- Unity Biotechnology (UBX)
Competitive Landscape
Telomir Pharmaceuticals faces competition from both established pharmaceutical companies and other biotech firms focusing on age-related diseases. Its competitive advantage hinges on the novelty and efficacy of its therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: There is no historical growth to report for sales. The company is pre-revenue. Growth depends on successful development of drug candidate
Future Projections: Future growth projections depend on the successful development and commercialization of Telomir-1 and other potential drug candidates. Analyst estimates would need to be consulted.
Recent Initiatives: Recent strategic initiatives would include clinical trial preparations, fundraising activities, and partnerships. Refer to latest news releases.
Summary
Telomir Pharmaceuticals is a pre-clinical stage company targeting age-related diseases with a novel therapeutic approach. Its success depends on the successful development and commercialization of Telomir-1 and securing funding. Its weaknesses are its pre-clinical status and limited resources, which must be balanced against the opportunities in the growing market for aging-related therapeutics. Telomir Pharmaceuticals must successfully navigate regulatory hurdles, competition, and funding challenges to realize its growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Press releases
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data may be outdated. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telomir Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2024-02-09 | Chairman of the Board & CEO Mr. Erez Aminov | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telomirpharma.com |
Full time employees - | Website https://telomirpharma.com |
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.